Metabolite profile resulting from the activation/inactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 2-methyltetrahydro- β -carboline by oxidative enzymes

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Herraiz, Tomás ^a   Guillén, Hugo ^a   Galisteo, Juan ^a  

^a CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 METHYLTETRAHYDRO BETA CARBOLINE; 2,3 DIHYDRO 1 METHYL 4 PHENYLPYRIDINIUM; AMINE OXIDASE (FLAVIN CONTAINING); CATION; CYTOCHROME P450; CYTOCHROME P450 2D6; LACTOPEROXIDASE; MYELOPEROXIDASE; OXIDOREDUCTASE; PROTOXIN; UNCLASSIFIED DRUG; 1-METHYL-4-PHENYL-2,3-DIHYDROPYRIDINIUM; 2-METHYLTRYPTOLINE; CARBOLINE DERIVATIVE; ENZYME; PEROXIDASE; PYRIDINIUM DERIVATIVE; 2 METHYLTRYPTOLINE;

ARTICLE; BIOTRANSFORMATION; CATALYSIS; CONTROLLED STUDY; DEMETHYLATION; HUMAN; HYDROXYLATION; METABOLITE; OXIDATION; TOXIN ANALYSIS; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METABOLOMICS; OXIDATION REDUCTION REACTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; CARBOLINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYMES; HUMANS; METABOLOMICS; MONOAMINE OXIDASE; OXIDATION-REDUCTION; PEROXIDASES; PYRIDINIUM COMPOUNDS;

EID: 84883168153     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/248608     Document Type: Article

References (71)

1. Langston J. W., Ballard P., Tetrud J. W., Irwin I., Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983 219 4587 979 980 2-s2.0-0020680904
2. Cannon J. R., Greenamyre J. T., The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicological Sciences 2011 124 2 225 250 2-s2.0-81855199724 10.1093/toxsci/kfr239
3. Moretto A., Colosio C., Biochemical and toxicological evidence of neurological effects of pesticides: the example of Parkinson's disease. NeuroToxicology 2011 32 4 383 391 2-s2.0-79955117911 10.1016/j.neuro.2011.03.004
4. Jackson-Lewis V., Przedborski S., Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols 2007 2 1 141 151 2-s2.0-34347259269 10.1038/nprot.2006.342
5. Kidd S. K., Schneider J. S., Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 2011 194 189 194 2-s2.0-80053105675 10.1016/j.neuroscience.2011.08.010
6. Mythri R. B., Veena J., Harish G., Rao B. S. S., Bharath M. M. S., Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo: implications for Parkinson's disease. British Journal of Nutrition 2011 106 1 63 72 2-s2.0-79960113178 10.1017/S0007114510005817
7. Blandini F., Armentero M.-T., Animal models of Parkinson's disease. FEBS Journal 2012 279 7 1156 1166 2-s2.0-84859108554 10.1111/j.1742-4658.2012.08491.x
8. +): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neuroscience Letters 1984 48 1 87 92 2-s2.0-0021263249
9. +) in discrete regions of murine brain. Toxicology Mechanisms and Methods 2011 21 3 171 182 2-s2.0-79951893475 10.3109/15376516.2010.538753
10. Ito T., Uchida K., Nakayama H., Neuronal or inducible nitric oxide synthase (NOS) expression level is not involved in the different susceptibility to nigro-striatal dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) between C57BL/6 and BALB/c mice. Experimental and Toxicologic Pathology 2013 65 1-2 121 125 2-s2.0-79960523786 10.1016/j.etp.2011.06.009
11. +) converted from MPTP through MAO-B. Experimental and Toxicologic Pathology 2012 64 7-8 761 765 2-s2.0-79751533614 10.1016/j.etp.2011.01.013
12. Gilham D. E., Cairns W., Paine M. J. I., Modi S., Poulsom R., Roberts G. C. K., Wolf C. R., Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997 27 1 111 125 2-s2.0-0031014344 10.1080/004982597240802
13. Weissman J., Trevor A., Chiba K., Peterson L. A., Caldera P., Castagnoli N. Jr., Baillie T., Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine by liver homogenate fractions. Journal of Medicinal Chemistry 1985 28 8 997 1001 2-s2.0-0021819789
14. Herraiz T., Guillén H., Arán V. J., Idle J. R., Gonzalez F. J., Comparative aromatic hydroxylation and N -demethylation of MPTP neurotoxin and its analogs, N -methylated β -carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Toxicology and Applied Pharmacology 2006 216 3 387 398 2-s2.0-33750079907 10.1016/j.taap.2006.06.003
15. Herraiz T., Guillén H., Galisteo J., N -methyltetrahydro- β -carboline analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin are oxidized to neurotoxic β -carbolinium cations by heme peroxidases. Biochemical and Biophysical Research Communications 2007 356 1 118 123 2-s2.0-33947141371 10.1016/j.bbrc.2007.02.089
16. Modi S., Gilham D. E., Sutcliffe M. J., Lian L.-Y., Primrose W. U., Wolf C. R., Roberts G. C. K., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 1997 36 15 4461 4470 2-s2.0-0030963409 10.1021/bi962633p
17. Bajpai P., Sangar M. C., Singh S., Metabolism of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease. The Journal of Biological Chemistry 2013 288 6 4436 4451 10.1074/jbc.M112.402123
18. Hanna I. H., Krauser J. A., Cai H., Kim M.-S., Guengerich F. P., Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6: lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. The Journal of Biological Chemistry 2001 276 43 39553 39561 2-s2.0-0035955733 10.1074/jbc.M106841200
19. Coleman T., Ellis S. W., Martin I. J., Lennard M. S., Tucker G. T., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N -demethylated by cytochromes P450 2D6, 1A2 and 3A4-implications for susceptibility to Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics 1996 277 2 685 690 2-s2.0-0030436624
20. Collins M. A., Neafsey E. J., β -carboline analogues of N -methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neuroscience Letters 1985 55 2 179 184 2-s2.0-0021992979 10.1016/0304-3940(85)90016-3
21. Herraiz T., Antkiewicz-Michaluk L., Rommelspacher H., β -carbolines as neurotoxins. Isoquinolines and β -Carbolines as Neurotoxins and Neuroprotectants: New Vistas in Parkinson's Disease Therapy 2012 1 Springer 77 103 Current Topics in Neurotoxicity
22. Herraiz T., Relative exposure to β -carbolines norharman and harman from foods and tobacco smoke. Food Additives and Contaminants 2004 21 11 1041 1050 2-s2.0-11944275594 10.1080/02652030400019844
23. Robinson E. S. J., Anderson N. J., Crosby J., Nutt D. J., Hudson A. L., Endogenous β -carbolines as clonidine-displacing substances. Annals of the New York Academy of Sciences 2003 1009 157 166 2-s2.0-1342284213 10.1196/annals.1304.018
24. Herraiz T., Chaparro C., Human monoamine oxidase is inhibited by tobacco smoke: β -carboline alkaloids act as potent and reversible inhibitors. Biochemical and Biophysical Research Communications 2005 326 2 378 386 2-s2.0-9944263390 10.1016/j.bbrc.2004.11.033
25. Herraiz T., Chaparro C., Human monoamine oxidase enzyme inhibition by coffee and β -carbolines norharman and harman isolated from coffee. Life Sciences 2006 78 8 795 802 2-s2.0-30544432396 10.1016/j.lfs.2005.05.074
26. Airaksinen M. M., Kari I., β -carbolines, psychoactive compounds in the mammalian body-part I: occurrence, origin and metabolism. Medical Biology 1981 59 1 21 34 2-s2.0-0019406904
27. Herraiz T., Galisteo J., Tetrahydro- β -carboline alkaloids occur in fruits and fruit juices. Activity as antioxidants and radical scavengers. Journal of Agricultural and Food Chemistry 2003 51 24 7156 7161 2-s2.0-0242691743 10.1021/jf030324h
28. Herraiz T., Occurrence of 1,2,3,4-tetrahydro- β -carboline-3- carboxylic acid and 1-methyl-1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid in fruit juices, purees, and jams. Journal of Agricultural and Food Chemistry 1998 46 9 3484 3490 2-s2.0-0001190575
29. Gearhart D. A., Collins M. A., Lee J. M., Neafsey E. J., Increased β -carboline 9 N -methyltransferase activity in the frontal cortex in Parkinson's disease. Neurobiology of Disease 2000 7 3 201 211 2-s2.0-0034210323 10.1006/nbdi.2000.0287
30. Wernicke C., Schott Y., Enzensperger C., Schulze G., Lehmann J., Rommelspacher H., Cytotoxicity of β -carbolines in dopamine transporter expressing cells: structure-activity relationships. Biochemical Pharmacology 2007 74 7 1065 1077 2-s2.0-34548119850 10.1016/j.bcp.2007.06.046
31. Pavlovic S., Schulze G., Wernicke C., Bonnet R., Gille G., Badiali L., Kaminska A., Lorenc-Koci E., Ossowska K., Rommelspacher H., 2,9-dimethyl- β -carbolinium, a neurotoxin occurring in human brain, is a potent inducer of apoptosis as 1-methyl-4-phenylpyridinium. Neuroscience 2006 139 4 1525 1537 2-s2.0-33646137553 10.1016/j.neuroscience.2006.01.018
32. Lorenc-Koci E., Rommelspacher H., Schulze G., Wernicke C., Kuter K., Śmiałowska M., Wierońska J., Ziba B., Ossowska K., Parkinson's disease-like syndrome in rats induced by 2,9-dimethyl- β-carbolinium ion, a β -carboline occurring in the human brain. Behavioural Pharmacology 2006 17 5-6 463 473 2-s2.0-33748313157 10.1097/00008877-200609000-00012
33. Storch A., Hwang Y.-I., Gearhart D. A., Beach J. W., Neafsey E. J., Collins M. A., Schwarz J., Dopamine transporter-mediated cytotoxicity of β -carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake. Journal of Neurochemistry 2004 89 3 685 694 2-s2.0-2042423928
34. Matsubara K., Collins M. A., Akane A., Ikebuchi J., Neafsey E. J., Kagawa M., Shiono H., Potential bioactivated neurotoxicants, N -methylated β -carbolinium ions, are present in human brain. Brain Research 1993 610 1 90 96 2-s2.0-0027252719 10.1016/0006-8993(93)91221-D
35. + analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 1995 45 12 2240 2245 2-s2.0-0029440852
36. Matsubara K., Gonda T., Sawada H., Uezono T., Kobayashi Y., Kawamura T., Ohtaki K.-I., Kimura K., Akaike A., Endogenously occurring β -carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease. Journal of Neurochemistry 1998 70 2 727 735 2-s2.0-0031952527
37. Youdim M. B. H., Edmondson D., Tipton K. F., The therapeutic potential of monoamine oxidase inhibitors. Nature Reviews Neuroscience 2006 7 4 295 309 2-s2.0-33645307953 10.1038/nrn1883
38. Naoi M., Maruyama W., Inaba-Hasegawa K., Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. Current Topics in Medicinal Chemistry 2012 12 20 2177 2188
39. Lieu C. A., Chinta S. J., Rane A., Andersen J. K., Age-related behavioral phenotype of an astrocytic monoamine oxidase-B transgenic mouse model of Parkinson's Disease. PLoS ONE 2013 8 1, article e54200 10.1371/journal.pone. 0054200
40. Weinreb O., Amit T., Bar-Am O., Youdim M. B. H., Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Progress in Neurobiology 2010 92 3 330 344 2-s2.0-77956092544 10.1016/j.pneurobio.2010.06.008
41. Mallajosyula J. K., Kaur D., Chinta S. J., Rajagopalan S., Rane A., Nicholls D. G., Di Monte D. A., Macarthur H., Andersen J. K., MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS ONE 2008 3 2, article e1616 2-s2.0-45749101293 10.1371/journal.pone.0001616
42. Yu A.-M., Idle J. R., Byrd L. G., Krausz K. W., Küpfer A., Gonzalez F. J., Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003 13 3 173 181 2-s2.0-0037342251 10.1097/00008571-200303000-00007
43. Yu A.-M., Idle J. R., Herraiz T., Küpfer A., Gonzalez F. J., Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O -demethylase. Pharmacogenetics 2003 13 6 307 319 2-s2.0-0038240578 10.1097/00008571-200306000-00002
44. McCann S. J., Pond S. M., James K. M., le Couteur D. G., The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. Journal of the Neurological Sciences 1997 153 1 50 53 2-s2.0-0031472072 10.1016/S0022-510X(97)00179-2
45. Elbaz A., Levecque C., Clavel J., Vidal J.-S., Richard F., Amouyel P., Alpérovitch A., Chartier-Harlin M.-C., Tzourio C., CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Annals of Neurology 2004 55 3 430 434 2-s2.0-1442329302 10.1002/ana.20051
46. Mann A., Tyndale R. F., Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. European Journal of Neuroscience 2010 31 7 1185 1193 2-s2.0-77950419280 10.1111/j.1460-9568. 2010.07142.x
47. Tafazoli S., O'Brien P. J., Peroxidases: a role in the metabolism and side effects of drugs. Drug Discovery Today 2005 10 9 617 625 2-s2.0-18944406318 10.1016/S1359-6446(05)03394-5
48. Green P. S., Mendez A. J., Jacob J. S., Crowley J. R., Growdon W., Hyman B. T., Heinecke J. W., Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. Journal of Neurochemistry 2004 90 3 724 733 2-s2.0-3343003470 10.1111/j.1471-4159.2004.02527.x
49. Choi D.-K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.-C., Jackson-Lewis V., Vila M., Vonsattel J.-P., Heinecke J. W., Przedborski S., Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. Journal of Neuroscience 2005 25 28 6594 6600 2-s2.0-22244434468 10.1523/JNEUROSCI.0970-05.2005
50. Huh S. H., Chung Y. C., Piao Y., Jin M. Y., Son H. J., Yoon N. S., Hong J. Y., Pak Y. K., Kim Y. S., Hong J. K., Hwang O., Jin B. K., Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. Journal of Immunology 2011 187 2 960 969 2-s2.0-79960501774 10.4049/jimmunol.1100009
51. Galzigna L., Schiappelli M. P., Rigo A., Scarpa M., A rat brain fraction and different purified peroxidases catalyzing the formation of dopaminochrome from dopamine. Biochimica et Biophysica Acta 1999 1427 3 329 336 2-s2.0-0032893232 10.1016/S0304-4165(99)00037-9
52. Everse J., Coates P. W., Role of peroxidases in Parkinson disease: a hypothesis. Free Radical Biology and Medicine 2005 38 10 1296 1310 2-s2.0-18044388917 10.1016/j.freeradbiomed.2005.01.018
53. Jantschko W., Furtmüller P. G., Allegra M., Livrea M. A., Jakopitsch C., Regelsberger G., Obinger C., Redox intermediates of plant and mammalian peroxidases: a comparative transient-kinetic study of their reactivity toward indole derivatives. Archives of Biochemistry and Biophysics 2002 398 1 12 22 2-s2.0-0036478818 10.1006/abbi.2001.2674
54. Herraiz T., Guillén H., Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors. Food and Chemical Toxicology 2011 49 8 1773 1781 2-s2.0-79958762778 10.1016/j.fct.2011.04.026
55. Heikkila R. E., Manzino L., Cabbat F. S., Duvoisin R. C., Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984 311 5985 467 469 2-s2.0-0021224694
56. Herraiz T., Evaluation of the oxidation of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) to toxic pyridinium cations by monoamine oxidase (MAO) enzymes and its use to search for new MAO inhibitors and protective agents. Journal of Enzyme Inhibition and Medicinal Chemistry 2012 27 6 810 817
57. di Monte D. A., Wu E. Y., Irwin I., Delanney L. E., Langston J. W., Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. Journal of Pharmacology and Experimental Therapeutics 1991 258 2 594 600 2-s2.0-0026048074
58. + the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Journal of Medicinal Chemistry 1985 28 10 1432 1436 2-s2.0-0022372075
59. Herraiz T., Galisteo J., Tetrahydro- β -carboline alkaloids that occur in foods and biological systems act as radical scavengers and antioxidants in the ABTS assay. Free Radical Research 2002 36 8 923 928 2-s2.0-0036681598 10.1080/1071576021000005762
60. Jimenez-Jimenez F. J., Tabernero C., Mena M. A., Garcia de Yebenes J., Garcia de Yebenes M. J., Casarejos M. J., Pardo B., Garcia-Agundez J. A., Benitez J., Martinez A., Lopez Garcia-Asenjo J. A., Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. Journal of Neurochemistry 1991 57 1 81 87 2-s2.0-0025990306
61. Inoue H., Castagnoli K., van der Schyf C., Mabic S., Igarashi K., Castagnoli N. Jr., Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridinyl derivatives. Journal of Pharmacology and Experimental Therapeutics 1999 291 2 856 864 2-s2.0-0032696105
62. Everse J., Liu C.-J. J., Coates P. W., Physical and catalytic properties of a peroxidase derived from cytochrome c. Biochimica et Biophysica Acta 2011 1812 9 1138 1145 2-s2.0-79960565354 10.1016/j.bbadis.2011.05.003
63. Lefkowitz D. L., Lefkowitz S. S., Microglia and myeloperoxidase: a deadly partnership in neurodegenerative disease. Free Radical Biology and Medicine 2008 45 5 726 731 2-s2.0-48449094379 10.1016/j.freeradbiomed.2008.05.021
64. Mann A., Miksys S. L., Gaedigk A., Kish S. J., Mash D. C., Tyndale R. F., The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiology of Aging 2012 33 9 2160 2171 2-s2.0-80053365159 10.1016/j.neurobiolaging.2011.08.014
65. Perry T. L., Jones K., Hansen S., Wall R. A., 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets. Neuroscience Letters 1987 75 1 65 70 2-s2.0-0023148530
66. Herraiz T., González D., Ancín-Azpilicueta C., Arán V. J., Guillén H., β -carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food and Chemical Toxicology 2010 48 3 839 845 2-s2.0-76749127951 10.1016/j.fct.2009.12.019
67. Herraiz T., Tetrahydro- β -carboline-3-carboxylic acid compounds in fish and meat: possible precursors of co-mutagenic β -carbolines norharman and harman in cooked fools. Food Additives and Contaminants 2000 17 10 859 866 2-s2.0-0033824533
68. Louis E. D., Rios E., Pellegrino K. M., Jiang W., Factor-Litvak P., Zheng W., Higher blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations correlate with lower olfactory scores in essential tremor. NeuroToxicology 2008 29 3 460 465 2-s2.0-44649145107 10.1016/j.neuro.2008.02.013
69. Matsubara K., Collins M. A., Neafsey E. J., Mono- N -methylation of 1,2,3,4-tetrahydro- β -carbolines in brain cytosol: absence of indole methylation. Journal of Neurochemistry 1992 59 2 505 510 2-s2.0-0026764244 10.1111/j.1471-4159.1992.tb09399.x
70. Barker S. A., Harrison R. E. W., Monti J. A., Brown G. B., Christian S. T., Identification and quantification of 1,2,3,4-tetrahydro- β -carboline, 2-methyl-1,2,3,4-tetrahydro- β -carboline and 6-methoxy-1,2,3,4-tetrahydro- β -carboline as in vivo constituents of rat brain and adrenal gland. Biochemical Pharmacology 1981 30 1 9 17 2-s2.0-0019377920 10.1016/0006-2952(81) 90278-1
71. Hamann J., Rommelspacher H., Storch A., Reichmann H., Gille G., Neurotoxic mechanisms of 2,9-dimethyl- β -carbolinium ion in primary dopaminergic culture. Journal of Neurochemistry 2006 98 4 1185 1199 2-s2.0-33746398090 10.1111/j.1471-4159.2006.03940.x